Access comprehensive financial analyses and make smarter investments - get the Manual of Investments on Amazon!

ARR

Armour Residential REIT – A Closer Look

Armour Residential REIT ended May with a $22.2 billion portfolio that was 93.8% agency mortgage-backed securities, including $19.5 billion of 30-year fixed-rate pools and $1.3 billion of agency CMBS.

Within the agency book, 30-year fixed-rate pools made up 87.9% of the portfolio. The largest concentration was in 30-year 5.5% pools at $5.7 billion, or 25.6% of the portfolio, followed by 30-year 5.0% pools at $4.1 billion, or 18.6%, and 30-year 6.0% pools at $3.6 billion, or 16.2%.

The company’s leverage stood at 7.9 times debt-to-equity, with implied leverage at 8.0 times. Liquidity totaled $1.16 billion, equal to 46% of total capital. Market capitalization was $2.06 billion, and the common stock traded at $17.15.

Armour declared a June common dividend of $0.24 a share, implying a current dividend yield of 16.8%.

On the funding side, total repo borrowings were $19.87 billion. Buckler Securities provided $9.29 billion, or 46.8% of repo positions, while all other counterparties supplied $10.57 billion, or 53.2%. The weighted average original repo term was 58 days, with 37 days remaining and a longest maturity of 981 days across all counterparties.

The company’s swap book totaled $15.34 billion in notional value. The largest tranche was $3.59 billion maturing in 25 to 36 months, with a weighted average rate of 3.53% and 30.3 months remaining. Another $2.50 billion matured in 13 to 24 months at 3.62%, while $2.15 billion ran 49 to 60 months at 0.93%. The longest-dated swap bucket, beyond 120 months, totaled $775 million at 4.22%.

Treasury longs added another $982 million to the portfolio, while net TBA positions were $399 million. As a result of these announcements, the company's shares have moved -0.17% on the market, and are now trading at a price of $17.10. Check out the company's full 8-K submission here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS